Physician profile
Leanne Murray
NPI 1689195463
$2,658.80
in general payments reported to CMS, 2019-2025
31 companies · $536 in 2025
The $536 reported for 2025 was more than what 76% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $498 · 2023: $789 · 2024: $349 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.79 |
| Education | $119.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.59 | 2021-2025 | |
| Astellas Pharma US INC | $341.20 | 2022-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $214.19 | 2022-2025 | |
| Exeltis, USA INC. | $196.42 | 2021-2025 | Slynd |
| Myriad Women'S Health, INC. | $157.11 | 2023 | Myrisk |
| Astrazeneca Pharmaceuticals Lp | $135.84 | 2025 | Airsupra, Farxiga |
| Sage Therapeutics, LLC | $126.56 | 2024-2025 | Zurzuvae |
| Organon LLC | $115.63 | 2022-2024 | Nexplanon |
| Sumitomo Pharma America, INC. | $111.74 | 2023-2025 | Myfembree, Gemtesa |
| Amgen INC. | $108.18 | 2021-2023 | Evenity, Prolia |
| Lilly USA, LLC | $83.26 | 2021-2023 | Mounjaro |
| Hologic Sales and Service, LLC | $82.13 | 2023-2025 | Aptima |
| Therapeuticsmd, INC. | $51.80 | 2021-2022 | |
| Daiichi Sankyo INC. | $40.03 | 2021 | |
| Abbott Laboratories | $33.69 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $29.74 | 2021 | |
| Merck Sharp & Dohme LLC | $27.92 | 2021 | |
| Supernus Pharmaceuticals, INC. | $24.51 | 2025 | Qelbree |
| Millicent US INC | $23.70 | 2025 | Intrarosa, Femring |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.88 | 2022 | |
| Genentech USA, INC. | $22.12 | 2021 | |
| Agile Therapeutics, INC. | $20.86 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.74 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $19.53 | 2024 | |
| Pfizer INC. | $18.16 | 2025 | |
| Smith+Nephew, INC. | $18.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.17 | 2021 | |
| Alfasigma USA, INC. | $14.67 | 2022 | |
| Novo Nordisk INC | $13.87 | 2023 | |
| Scynexis, INC. | $13.77 | 2022 | |
| Evofem Biosciences, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanne Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.